ASCO GI 2021

ASCO Gastrointestinal Cancers Symposium 2021

At the 2021 ASCO GI virtual meeting, Boehringer Ingelheim presented the latest data on their cancer research program across multiple tumor types, including gastric and esophageal cancer.


Please see below for more information and downloadable versions of these publications.

Virtual exhibit


Click here to view our latest virtual exhibit.

Friday 15 January – Sunday 17 January, 2021
Virtual format

Explore our latest clinical data presented during the scientific program at ASCO GI 2021.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Friday 15 January – Sunday 17 January, 2021
Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer.
Author(s): Yamaguchi et al.
Poster Presentation
Tumor Type(s): esophageal and gastric cancer
Presentation Number: 212
Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: combination with BI 836880, a VEGF/Ang2-blocking nanobody®.
Author(s): Hussein et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: TPS152
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.


Pipeline compounds shown here are under pre-clinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.


© 2021 Boehringer Ingelheim International GmbH. All rights reserved.


Page last updated: January 2021